Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-05-2024 | Cervical Cancer | Research

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Authors: Ning Zhao, Yunhai Li, MD, Xue Chen, Jinli Ma, Weiming Luo, Yunhai Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2024

Abstract

Objective

A preclinical study showed that nab-paclitaxel acted as a radiosensitizer and improved tumor radiotherapy in a supra-additive manner. In this study, we aimed to evaluate the clinical efficacy and safety of concurrent chemoradiotherapy (CCRT) with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer with an unfavorable prognosis.

Methods

Eligible patients with stage IB1-IIA2 (FIGO 2009) cervical carcinoma were recruited retrospectively between August 2018 to May 2021. Patients in both the cisplatin and nab-paclitaxel groups received postoperative radiotherapy and weekly intravenous cisplatin 40 mg/m² or nab-paclitaxel 100 mg concurrently. An analysis of overall survival, progression-free survival, and adverse reactions was conducted.

Results

A total of 105 early-stage cervical cancer patients were included into our study. The median follow-up time was 38.7 months. The 3-year overall survival and progression-free survival in both group was similar. The cycles of chemotherapy in the cisplatin group were less than those in the nab-paclitaxel group (4.5 vs. 5.0; p = 0.001). Patients in the cisplatin group had a significantly higher frequency of hematological adverse events than patients in the nab-paclitaxel group (P < 0.05). Patients in the cisplatin group had a significantly higher frequency of grade 3–4 leukopenia (46.1% vs. 18.9%; P = 0.03), grade 1–2 thrombocytopenia (32.7% vs. 9.5%; P = 0.014) than patients in the nab-paclitaxel group. Gastrointestinal reactions, such as vomiting, nausea, and anorexia were significantly reduced in the nab-paclitaxel group compared with those in the cisplatin group. Regarding the effects on alopecia, the incidence rate of the nab-paclitaxel group was higher than that of the cisplatin group (P = 0.001). There were no differences between the groups in terms of other adverse reactions.

Conclusion

The results of this study indicate that nab-paclitaxel-based concurrent radiotherapy is tolerable and effective, and can be considered an alternative to cisplatin chemotherapy.

Alberts DS, Blessing JA, Landrum LM et al (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 127:451–455CrossRefPubMedPubMedCentral

Arbyn M, Weiderpass E, Bruni L et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:e191–e203CrossRefPubMed

Cao L, Wen H, Feng Z et al (2021) Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer. Int J Gynecol Cancer 31:52–58CrossRefPubMed

Cecco S, Aliberti M, Baldo P et al (2014) Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Safety 13:511–520CrossRef

Colombo N, Van Gorp T, Matulonis UA et al (2023) Relacorilant +nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study. J Clin Oncol 41:4779–4789CrossRefPubMedPubMedCentral

Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentration and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324CrossRefPubMed

Desai N, Trieu V, Damascelli B et al (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2:59–64CrossRefPubMedPubMedCentral

Fader AN, Rose PG (2009) Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 19:1281–1283CrossRefPubMed

Gardner ER, Dahut WL, Scripture CD et al (2008) Randomized crossover pharmacokinetic study of solvent based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200–4205CrossRefPubMedPubMedCentral

Gelderblom H, Verweij J, Nooter K et al (2001) Cremophor EL:the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598CrossRefPubMed

Gong W, Sun P, Zhengbin Mu et al (2017) Efficacy and safety of nab-paclitaxel as second-line chemotherapy for locally advanced and metastatic non-small cell lung cancer. Anticancer Res 37:4687–4691PubMed

Gradishar WJ, Tjudlandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803CrossRefPubMed

Gurses N, Topcul M (2013) The effect of abraxane on cell kinetic parameters of HeLa cells. Asian Pac J Cancer Prev 14:4229–4233CrossRefPubMed

Han J, Zakeri K, Raab G et al (2023) Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head Neck 45:2207–2216CrossRefPubMedPubMedCentral

Jiang XD, Ang Q et al (2023) Image guidance volume-modulated arc radiation therapy concurrently with nab-paclitaxel plus cisplatin for patients with locally advanced cervical cancer: a single-arm dose escalation trial. Int J Radiat Oncol Biol Phys. 115:1197–1204CrossRefPubMed

Keys HM, Bundy BN, Stehman FB et al (1999) Cisplatin, radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161CrossRefPubMed

Kim K, Chie EK, Wu HG et al (2006) Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol 101:398–402CrossRefPubMed

Kim H, Park W, Kim YS et al (2020) Chemoradiotherapy is not superior to radiotherapy alone after radical surgeryfor cervical cancer patients with intermediate-risk factor. J Gynecol Oncol 31:e35CrossRefPubMed

Koay EJ, Zaid M, Aliru M et al (2022) Nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in treating patients with locally advanced and borderline resectable pancreatic cancer: phase 1 trial and imaging-based biomarker validation. Int J Radiat Oncol Biol Phys 114:444–453CrossRefPubMed

Li Y, Liu Y, Lu P et al (2021) Research progress of nanoparticle albumin bound paclitaxel in neoadjuvant chemotherapy for cervical cancer. J Int Obstet Gynecol. 48:135–138

Li JJ, Wang JH, Dingv Y et al (2022) Efficacy and safety of anti-PD-1 inhibitor combined with nab- paclitaxel in Chinese patients with refractory melanoma. J Cancer Res Clin Oncol 148:1159–1169CrossRefPubMed

Liang J, Bi N, Wu S et al (2017) Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 28:777–783CrossRefPubMed

Mandloi V, Yogi V, Singh OP et al (2019) A comparative study of nab-paclitaxel versus cisplatin concurrent chemoradiotherapy in locally advanced cervical cancer. Clin Cancer Investig J 8:198–204CrossRef

Minshall RD, Tiruppathi C, Vogel SM et al (2002) Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol 117:105–112CrossRefPubMed

Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143CrossRefPubMed

Okazawa M, Mabuchi S, Isohashi F et al (2013) Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer 23:567–575CrossRefPubMed

Oppelt P, Ley J, Daly M et al (2021) Nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Med Oncol 38:35CrossRefPubMed

Peters WA, Liu PY, Barrett RJ et al (2023) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 41:4605–4612CrossRefPubMed

Rodriguez J, Viveros-Carreño D, Pareja R et al (2022) Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update? Int J Gynecol Cancer 32:1219–1226CrossRefPubMed

Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153CrossRefPubMed

Sedlis A, Bundy BN, Rotman MZ et al (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73:177–183CrossRefPubMed

Sparreboom A, Scripture CD, Treiu V et al (2005) Comparative preclinical and clinical pharmacokinetics of a Cremophorfree, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in Cremophor (Taxol). Clin CancerRes 11:4136–4143CrossRef

Sugawara S, Lee JS, Kang JH et al (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 32:1137–1147CrossRefPubMed

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed

Suntharalingam M, Kwok Y, Goloubeva O et al (2012) Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 82:1845–1850CrossRefPubMed

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef

Wiedenmann N, Valdecanas D, Hunter N et al (2007) One hundred thirty-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 13:1868–1874CrossRefPubMed

Title: Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer
Authors: Ning Zhao
Yunhai Li, MD
Xue Chen
Jinli Ma
Weiming Luo
Yunhai Li
Publication date: 01-05-2024
Publisher: Springer Berlin Heidelberg
Keywords: Cervical Cancer
Cervical Cancer
Radiotherapy
Cytostatic Therapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-024-05764-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary

Study on carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma

Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma

BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation

Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis

Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials